Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of $10.02 billion. The enterprise value is $2.37 billion.
Important Dates
The next estimated earnings date is Thursday, July 31, 2025, before market open.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Moderna has 386.74 million shares outstanding. The number of shares has increased by 1.05% in one year.
| Current Share Class | 386.74M |
| Shares Outstanding | 386.74M |
| Shares Change (YoY) | +1.05% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 6.59% |
| Owned by Institutions (%) | 74.04% |
| Float | 360.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.14 |
| Forward PS | 4.66 |
| PB Ratio | 1.00 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.22, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.22 |
| Quick Ratio | 3.92 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -196.26 |
Financial Efficiency
Return on equity (ROE) is -29.34% and return on invested capital (ROIC) is -18.75%.
| Return on Equity (ROE) | -29.34% |
| Return on Assets (ROA) | -15.84% |
| Return on Invested Capital (ROIC) | -18.75% |
| Return on Capital Employed (ROCE) | -33.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.22 |
| Inventory Turnover | 27.39 |
Taxes
| Income Tax | -49.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.57% in the last 52 weeks. The beta is 1.86, so Moderna's price volatility has been higher than the market average.
| Beta (5Y) | 1.86 |
| 52-Week Price Change | -80.57% |
| 50-Day Moving Average | 26.30 |
| 200-Day Moving Average | 40.29 |
| Relative Strength Index (RSI) | 46.10 |
| Average Volume (20 Days) | 10,891,407 |
Short Selling Information
The latest short interest is 65.86 million, so 17.03% of the outstanding shares have been sold short.
| Short Interest | 65.86M |
| Short Previous Month | 67.27M |
| Short % of Shares Out | 17.03% |
| Short % of Float | 18.24% |
| Short Ratio (days to cover) | 4.73 |
Income Statement
In the last 12 months, Moderna had revenue of $3.18 billion and -$3.36 billion in losses. Loss per share was -$8.73.
| Revenue | 3.18B |
| Gross Profit | -2.62B |
| Operating Income | -3.73B |
| Pretax Income | n/a |
| Net Income | -3.36B |
| EBITDA | -3.54B |
| EBIT | -3.73B |
| Loss Per Share | -$8.73 |
Full Income StatementBalance Sheet
The company has $5.98 billion in cash and $745.00 million in debt, giving a net cash position of $7.65 billion or $19.78 per share.
| Cash & Cash Equivalents | 5.98B |
| Total Debt | 745.00M |
| Net Cash | 7.65B |
| Net Cash Per Share | $19.78 |
| Equity (Book Value) | 10.07B |
| Book Value Per Share | 26.01 |
| Working Capital | 5.16B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.05 billion and capital expenditures -$972.00 million, giving a free cash flow of -$4.02 billion.
| Operating Cash Flow | -3.05B |
| Capital Expenditures | -972.00M |
| Free Cash Flow | -4.02B |
| FCF Per Share | -$10.40 |
Full Cash Flow StatementMargins
Gross margin is -82.37%, with operating and profit margins of -117.37% and -105.67%.
| Gross Margin | -82.37% |
| Operating Margin | -117.37% |
| Pretax Margin | -107.21% |
| Profit Margin | -105.67% |
| EBITDA Margin | -111.33% |
| EBIT Margin | -117.37% |
| FCF Margin | n/a |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.05% |
| Shareholder Yield | -1.05% |
| Earnings Yield | -33.51% |
| FCF Yield | -40.17% |
Dividend DetailsAnalyst Forecast
The average price target for Moderna is $48.13, which is 85.83% higher than the current price. The consensus rating is "Hold".
| Price Target | $48.13 |
| Price Target Difference | 85.83% |
| Analyst Consensus | Hold |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 17.84% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 7.39 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.39 |
| Piotroski F-Score | 2 |